Consensus BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.63 ^USD	+0.77%		-4.36%	-10.85%

Apr. 22	BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	MT
Apr. 22	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	CI

Evolution of the average Target Price on BioXcel Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

979d16.hX65BBBPQDvEy0pHhSSqUoESSNBVhYeyA-XcpBJN_fo.8TDSPGYAH06phwVy_1KcFPReL5ls__XiSo-b00Z9pM_JTvtreCA2eo6vGw~ac6d9d57562c0ddf95df9231d6d6d3b8

Analyst Recommendations on BioXcel Therapeutics, Inc.

Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating	Mar. 14	MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating	Mar. 13	MT
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9	Feb. 21	MT
Truist Securities Downgrades BioXcel Therapeutics to Hold From Buy	23-10-05	MT
HC Wainwright Lowers Price Target on BioXcel Therapeutics to $11 From $60, Maintains Buy Rating	23-08-18	MT
UBS Adjusts BioXcel Therapeutics Price Target to $9 From $48, Maintains Buy Rating	23-08-16	MT
Goldman Sachs Cuts Price Target on BioXcel Therapeutics to $4 From $12, Maintains Neutral Rating	23-08-15	MT
Truist Securities Adjusts Price Target on BioXcel Therapeutics to $31 From $71, Keeps Buy Rating	23-08-15	MT
Canaccord Genuity Adjusts Price Target on BioXcel Therapeutics to $20 From $75, Keeps Buy Rating	23-08-15	MT
Mizuho Downgrades BioXcel Therapeutics to Neutral From Buy Amid Restructuring and Strategic Reprioritization, Slashes Price Target to $4 From $40	23-08-15	MT
Guggenheim Downgrades BioXcel Therapeutics to Neutral From Buy	23-07-17	MT
HC Wainwright Cuts Price Target on BioXcel Therapeutics to $60 From $66, Maintains Buy Rating	23-07-03	MT
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $25 From $28, Maintains Neutral Rating	23-05-26	MT
Mizuho Securities Adjusts BioXcel Therapeutics Price Target to $40 From $38, Maintains Buy Rating	23-05-10	MT
Guggenheim Adjusts Price Target on BioXcel Therapeutics to $46 From $50, Maintains Buy Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $66 From $79, Keeps Buy Rating	23-03-21	MT
UBS Adjusts BioXcel Therapeutics Price Target to $48 From $52, Maintains Buy Rating	23-03-13	MT
Jefferies Downgrades BioXcel Therapeutics to Hold From Buy, Adjusts Price Target to $22 From $20	23-03-10	MT
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $79 From $73, Maintains Buy Rating	23-02-21	MT
UBS Adjusts BioXcel Therapeutics Price Target to $52 From $23, Maintains Buy Rating	23-02-15	MT
Mizuho Securities Adjusts Price Target on BioXcel Therapeutics to $38 From $24, Maintains Buy Rating	23-02-08	MT
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $26 From $16, Maintains Neutral Rating	23-01-26	MT
BioXcel Therapeutics Says Combination Treatment Showed 'Encouraging Response Rate' in Prostate Cancer Phase 2 Trial	23-01-11	MT
HC Wainwright Cuts Price Target on BioXcel Therapeutics to $73 From $85, Reiterates Buy Rating	23-01-03	MT
Mizuho Ups Price Target on BioXcel Therapeutics to $24 From $18, Maintains Buy Rating	22-12-15	MT